Participants at the February 2011 meeting at the U.S. National Institutes of Health on Epstein-Barr virus (EBV) vaccine research recommend that future clinical trials have two goals: prevention of infectious mononucleosis and EBV-associated cancers, facilitated by identification of disease-predictive surrogate markers.
At a meeting held at the U.S. National Institutes of Health (NIH) on 1 February 2011, scientists from government, academia, and industry (1) assembled to discuss the merits of a vaccine for Epstein-Barr virus (EBV) and the opportunities and challenges for its development. Here, we highlight relevant clinical and epidemiological data and make recommendations for future EBV vaccine research and development.
Get the full article here: http://stm.sciencemag.org/content/3/107/107fs7.full.pdf
From: [J. I. Cohen, A. S. Fauci, H. Varmus, G. J. Nabel, Epstein-Barr Virus: An Important Vaccine Target for Cancer Prevention. Sci. Transl. Med. 3, 107fs7 (2011).]. Reprinted with permission from AAAS.